AZT treatment 'able to slow down Aids'
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE CONTROVERSY over the anti-Aids drug AZT took a new turn today when the New England Journal of Medicine reported that the treatment can slow down the disease if given early to people with the HIV virus.
Research carried out by the European- Australian Collaborative Group found the treatment appeared to cut in half the chances that patients' conditions would get worse over the next two years.
The investigations contradict the European-based Concord study of patients carrying the HIV virus but showing no Aids symptoms, which found no significant benefit from early therapy. That study was based on a different definition of worsening disease than the latest research.
Doctors agree that AZT eventually loses its power against the virus. But the authors of the latest study said the evidence suggests that when given early, the medicine is beneficial for two to three years.
Scientists working on the latest study, conducted on 993 HIV-infected volunteers in 11 countries, found after two years of treatment there was a 19 per cent chance the disease would get worse among AZT recipients.
However, the risk of disease progression was 34 per cent in those getting inactive placebos.
Another major study, begun in 1987 on 3,200 patients in the United States, found that early treatment with AZT appeared to help.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments